Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence
This preregistered randomised double-blind active placebo-controlled between-subjects study (n=21) measured brain activity while viewing facial stimuli in response to repeated and acute administration of ketamine (35mg/70kg) and midazolam (3.15mg/70kg), among patients with severe PTSD. Both midazolam and ketamine improved symptoms, which were most reliably predicted by the reduced excitation of the amygdala and ventromedial prefrontal cortex (vmPFC) during the processing of socio-emotional threat signals, but only ketamine-related improvement was associated with increased top-down inhibition of the amygdala by the vmPFC.
Authors
- James Murrough
- Dennis Charney
- Manohar Jha
Published
Abstract
Introduction
Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic stress disorder (PTSD).
Methods
Here, we explore the neural correlates of ketamine-related changes in PTSD symptoms, using a rich battery of functional imaging data (two emotion-processing tasks and one task-free scan), collected from a subset of participants of a randomized clinical trial of repeated-dose intravenous ketamine vs midazolam (total N = 21). In a pre-registered analysis, we tested whether changes in an a priori set of imaging measures from a target neural circuit were predictive of improvement in PTSD symptoms, using leave-one-out cross-validated elastic-net regression models (regions of interest in the target circuit consisted of the dorsal and rostral anterior cingulate cortex, ventromedial prefrontal cortex, anterior hippocampus, anterior insula, and amygdala).
Results
Improvements in PTSD severity were associated with increased functional connectivity between the ventromedial prefrontal cortex (vmPFC) and amygdala during emotional face-viewing (change score retained in model with minimum predictive error in left-out subjects, standardized regression coefficient [β] = 2.90). This effect was stronger in participants who received ketamine compared to midazolam (interaction β = 0.86), and persisted following inclusion of concomitant change in depressive symptoms in the analysis model (β = 0.69). Improvement following ketamine was also predicted by decreased dorsal anterior cingulate activity during emotional conflict regulation, and increased task-free connectivity between the vmPFC and anterior insula (βs = −2.82, 0.60). Exploratory follow-up analysis via dynamic causal modelling revealed that whilst improvement in PTSD symptoms following either drug was associated with decreased excitatory modulation of amygdala→vmPFC connectivity during emotional face-viewing, increased top-down inhibition of the amygdala by the vmPFC was only observed in participants who improved under ketamine. Individuals with low prefrontal inhibition of amygdala responses to faces at baseline also showed greater improvements following ketamine treatment.
Discussion
These preliminary findings suggest that, specifically under ketamine, improvements in PTSD symptoms are accompanied by normalization of hypofrontal control over amygdala responses to social signals of threat.
Research Summary of 'Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence'
Introduction
Norbury and colleagues situate the study in emerging evidence that intravenous ketamine can reduce symptoms of post-traumatic stress disorder (PTSD) beyond its antidepressant effects. They note that ketamine may promote synaptogenesis and a transient state of increased neuroplasticity in medial prefrontal and hippocampal circuits, which could facilitate un- or re-learning processes such as extinction of fear memories. Prior imaging work in depression and PTSD has implicated altered prefrontal–amygdala circuitry during emotional processing, but neural correlates of symptomatic change after ketamine treatment in PTSD had not been reported. This paper reports a preliminary, hypothesis-driven analysis of functional MRI data collected before and after repeated-dose intravenous ketamine or midazolam in a subset of participants from a randomised clinical trial (N = 21). Using an a priori target circuit (vmPFC, rACC, dACC, anterior insula, anterior hippocampus, amygdala) and pre-registered analytic procedures, the investigators sought to identify imaging measures that correlate with or predict PTSD symptom change. Exploratory follow-up analyses, including dynamic causal modelling, were used to probe symptom specificity and the directionality of connectivity effects.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Norbury, A., Rutter, S. B., Collins, A. B., Costi, S., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Glasgow, A. M., Brallier, J., Shin, L. M., Charney, D. S., Murrough, J. W., & Feder, A. (2021). Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology, 46(13), 2266-2277. https://doi.org/10.1038/s41386-021-01104-4
References (7)
Papers cited by this study that are also in Blossom
Feder, A., Costi, S., Rutter, S. B. et al. · American Journal of Psychiatry (2021)
Ari, A., Abdallah, C. G., Sanacora, G. et al. · Annual Review of Medicine (2014)
Krystal, J. H., Abdallah, C. G., Averill, L. A. et al. · Current Psychiatry Reports (2017)
Fattore, L., Piva, A., Zanda, M. T. et al. · Psychopharmacology (2017)
Murrough, J. W., Collins, K. A., Fields, J. et al. · Translational Psychiatry (2015)
Reed, L. J., Nugent, A. C., Furey, M. et al. · Biological Psychiatry (2019)
Girgenti, M. J., Ghosal, S., Lopresto, D. et al. · Neurobiology of Disease (2017)
Cited By (2)
Papers in Blossom that reference this study
Hartland, H., Mahdavi, K., Jelen, L. A. et al. · Journal of Psychopharmacology (2023)
Shiroma, P. R., Velit-Salazar, M. R., Vorobyov, Y. · Clinical Drug Investigation (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.